Movalis (Meloxicam)

Meloxicam, the active ingredient in Movalis, is a nonsteroidal anti-inflammatory drug presented as an oral tablet for oral use in the European market. It is approved for adult patients to treat inflammation and pain associated with rheumatoid arthritis, osteoarthritis, ankylosing spondylitis and acute pain episodes.

GNH USA supplies Movalis as a licensed, GDP‑compliant international pharmaceutical supplier, providing regulated, quality‑assured products to hospitals, pharmacies and clinics worldwide through validated distribution networks and supporting pharmacovigilance activities. The company adheres to WHO GMP guidelines and ensures timely delivery across multiple continents.

Meloxicam, an NSAID, is used to manage inflammatory musculoskeletal disorders.

- Rheumatoid arthritis: reduces joint pain, swelling and stiffness, improving functional ability. - Osteoarthritis: alleviates chronic joint discomfort and enhances mobility. - Ankylosing spondylitis: decreases spinal inflammation and pain, helping maintain posture. - Acute pain: provides short‑term relief of moderate pain such as postoperative or injury‑related discomfort.

Meloxicam may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Gastrointestinal discomfort: nausea, dyspepsia or abdominal pain. - Headache: mild to moderate intensity. - Dizziness or vertigo. - Skin rash: mild erythematous eruptions.

Serious or Rare Side Effects: - Gastrointestinal ulceration or bleeding. - Cardiovascular thrombotic events such as myocardial infarction or stroke. - Severe skin reactions including Stevens‑Johnson syndrome. - Renal impairment or acute kidney injury.

When prescribing meloxicam, clinicians should consider several precautionary measures to minimize risk.

- Assess gastrointestinal risk: evaluate history of